Book any lab test, get a free doctor consult credit. Consults launching soon.कोई भी लैब टेस्ट बुक करें, पाएं फ्री डॉक्टर कंसल्ट क्रेडिट। कंसल्ट जल्द शुरू हो रहे हैं।Book nowअभी बुक करें →T&C applyशर्तें लागू
Skip to content
  1. Home
  2. Health news

Sellas’ cancer vaccine extends survival in blood cancer trial, company says

The Hindu — Health · 19 Nov 2026 · 1 min read

Sellas’ cancer vaccine extends survival in blood cancer trial, company says
Image: The Hindu — Health

Sellas Life ‌Sciences said on Tuesday, November 17, 2026 that its ​experimental ⁠vaccine helped patients with a type of blood ‌cancer live longer in ‌a late-stage ‌trial.

The ⁠vaccine, called galinpepimut-S ⁠or GPS, was tested in patients with acute ​myeloid ‌leukaemia, a fast-growing cancer of the blood and bone marrow.

Patients ‌who received ​GPS lived a median of ⁠24 months, compared to 14.7 months ‌for those given the best available treatment, Sellas said.

The company plans to talk ‌to the U.

S.

Food ​and Drug Administration about seeking approval ⁠for the vaccine. ⁠Its shares were halted in premarket ‌trading.

← Back to health news